Huons Global Co., Ltd. (084110.KQ)
KRW 52100.0
(3.99%)
KRW 52100.0
(3.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 38.38 Billion KRW | 163.7% |
| 2022 | -60.25 Billion KRW | -1608.41% |
| 2021 | 3.99 Billion KRW | -90.64% |
| 2020 | 42.69 Billion KRW | 60.17% |
| 2019 | 26.65 Billion KRW | -8.58% |
| 2018 | 29.16 Billion KRW | 13.18% |
| 2017 | 25.76 Billion KRW | 12.9% |
| 2016 | 22.82 Billion KRW | -29.53% |
| 2015 | 32.38 Billion KRW | 54.71% |
| 2014 | 20.93 Billion KRW | 20.42% |
| 2013 | 17.38 Billion KRW | 160.72% |
| 2012 | 6.66 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 10.18 Billion KRW | -6.93% |
| 2024 Q1 | 10.94 Billion KRW | -14.13% |
| 2023 FY | 38.38 Billion KRW | 163.7% |
| 2023 Q1 | 6.7 Billion KRW | 109.03% |
| 2023 Q4 | 12.74 Billion KRW | 15.19% |
| 2023 Q2 | 7.87 Billion KRW | 17.37% |
| 2023 Q3 | 11.06 Billion KRW | 40.56% |
| 2022 Q4 | -74.26 Billion KRW | -1345.38% |
| 2022 Q1 | 5.58 Billion KRW | 139.05% |
| 2022 FY | -60.25 Billion KRW | -1608.41% |
| 2022 Q2 | 2.46 Billion KRW | -55.95% |
| 2022 Q3 | 5.96 Billion KRW | 142.29% |
| 2021 Q1 | 7.3 Billion KRW | -51.59% |
| 2021 Q2 | 6.55 Billion KRW | -10.33% |
| 2021 Q3 | 4.44 Billion KRW | -32.12% |
| 2021 Q4 | -14.3 Billion KRW | -421.78% |
| 2021 FY | 3.99 Billion KRW | -90.64% |
| 2020 Q2 | 9.5 Billion KRW | 36.82% |
| 2020 Q3 | 11.14 Billion KRW | 17.26% |
| 2020 Q4 | 15.09 Billion KRW | 35.35% |
| 2020 Q1 | 6.94 Billion KRW | 9.46% |
| 2020 FY | 42.69 Billion KRW | 60.17% |
| 2019 Q4 | 6.34 Billion KRW | -13.01% |
| 2019 Q3 | 7.29 Billion KRW | 19.24% |
| 2019 Q2 | 6.12 Billion KRW | -11.18% |
| 2019 Q1 | 6.89 Billion KRW | 150.84% |
| 2019 FY | 26.65 Billion KRW | -8.58% |
| 2018 FY | 29.16 Billion KRW | 13.18% |
| 2018 Q4 | 2.74 Billion KRW | -74.44% |
| 2018 Q3 | 10.74 Billion KRW | 24.64% |
| 2018 Q2 | 8.62 Billion KRW | 17.45% |
| 2018 Q1 | 7.34 Billion KRW | -7.71% |
| 2017 Q4 | 7.95 Billion KRW | 10.93% |
| 2017 Q1 | 4.46 Billion KRW | 70.5% |
| 2017 Q2 | 6.36 Billion KRW | 42.45% |
| 2017 Q3 | 7.16 Billion KRW | 12.68% |
| 2017 FY | 25.76 Billion KRW | 12.9% |
| 2016 Q2 | 1.68 Billion KRW | 47.79% |
| 2016 Q4 | 2.61 Billion KRW | -7.69% |
| 2016 Q3 | 2.83 Billion KRW | 68.45% |
| 2016 Q1 | 1.14 Billion KRW | 251.42% |
| 2016 FY | 22.82 Billion KRW | -29.53% |
| 2015 Q2 | 407.29 Million KRW | 13.81% |
| 2015 Q4 | -752.9 Million KRW | -155.38% |
| 2015 Q3 | 1.35 Billion KRW | 233.78% |
| 2015 FY | 32.38 Billion KRW | 54.71% |
| 2015 Q1 | 357.87 Million KRW | -92.98% |
| 2014 Q3 | 5.84 Billion KRW | 11.49% |
| 2014 Q1 | 4.74 Billion KRW | 84.38% |
| 2014 Q2 | 5.24 Billion KRW | 10.67% |
| 2014 Q4 | 5.09 Billion KRW | -12.88% |
| 2014 FY | 20.93 Billion KRW | 20.42% |
| 2013 Q2 | 4.56 Billion KRW | 20.21% |
| 2013 FY | 17.38 Billion KRW | 160.72% |
| 2013 Q1 | 3.79 Billion KRW | 141.49% |
| 2013 Q3 | 6.45 Billion KRW | 41.48% |
| 2013 Q4 | 2.57 Billion KRW | -60.17% |
| 2012 FY | 6.66 Billion KRW | 0.0% |
| 2012 Q4 | 1.57 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 297.574% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -494.602% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | -80.502% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 18.636% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 511.558% |
| Humedix Co., Ltd. | 24.82 Billion KRW | -54.644% |
| Boditech Med Inc. | 25.94 Billion KRW | -47.933% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 376.56% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 672.126% |
| Huons Co., Ltd. | 50.47 Billion KRW | 23.952% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | -49.434% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 418.229% |